Actelion, J&J Return to the Negotiating table

The transcript discusses the negotiations between J&J and Italian, focusing on the potential acquisition and the conditions of a CVR payment. It highlights the strategic interests of J&J and Santa Fe in rare disease franchises and the market dynamics influencing these deals. The discussion also touches on potential future deals and the evolving antitrust landscape, suggesting that companies may find it easier to pursue mergers and acquisitions in the near future.

What were the main reasons for J&J's interest in acquiring Actelion?

What conditions must be met for the CVR payment mentioned in the text?

How does the potential acquisition of Actelion align with J&J's growth strategy?

What impact could the acquisition have on Santa Fe's share price in the long term?

Which other companies are mentioned as potential targets for J&J if Actelion is acquired?